{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:07:05Z","timestamp":1794413225050,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Disruptions in gut microbiome are implicated in cardiometabolic disorders and other health outcomes. Antibiotics are known gut microbiome disruptors, but their long-term consequences remain underexplored. Here we combined individual-level data from the Swedish Prescribed Drug Register with fecal metagenomes of 14,979 adults to examine the association between oral antibiotic use over 8 years and gut microbiome. In multivariable confounder-adjusted regression models, antibiotic use &lt;1 year before fecal sampling was associated with the greatest reduction in species diversity, but significant associations were also observed for use 1\u20134 and 4\u20138 years earlier. Clindamycin, fluoroquinolones and flucloxacillin accounted for most of the associations with the abundance of individual species. Use of these antibiotics 4\u20138 years earlier was associated with altered abundance of 10\u201315% of the species studied; penicillin V, extended-spectrum penicillins and nitrofurantoin were associated with only a few species. Similar results were found comparing one antibiotic course 4\u20138 years before sampling versus none in the past 8 years. These findings indicate that antibiotics may have long-lasting consequences for the gut microbiome.<\/jats:p>","DOI":"10.1038\/s41591-026-04284-y","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:01:54Z","timestamp":1773223314000},"page":"1351-1361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-3953","authenticated-orcid":false,"given":"Gabriel","family":"Baldanzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7016-9802","authenticated-orcid":false,"given":"Anna","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Sayols-Baixeras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-7235","authenticated-orcid":false,"given":"Koen F.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Hammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diem","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00edscar","family":"Graells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafqat","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Gazolla Volpiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9958","authenticated-orcid":false,"given":"Guillaume","family":"Meric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7075-1059","authenticated-orcid":false,"given":"Josef D.","family":"J\u00e4rhult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-9849","authenticated-orcid":false,"given":"Thomas","family":"T\u00e4ngd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas F.","family":"Ludvigsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2247-8454","authenticated-orcid":false,"given":"Johan","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Micha\u00eblsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"\u00c4rnl\u00f6v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3578-2503","authenticated-orcid":false,"given":"Marju","family":"Orho-Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2071-5866","authenticated-orcid":false,"given":"Tove","family":"Fall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"4284_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01197-y","volume":"22","author":"J Nuotio","year":"2022","unstructured":"Nuotio, J. et al. Use of antibiotics and risk of type 2 diabetes, overweight and obesity: the Cardiovascular Risk in Young Finns Study and the national FINRISK study. BMC Endocr. Disord. 22, 284 (2022).","journal-title":"BMC Endocr. Disord."},{"key":"4284_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/ijo.2015.218","volume":"40","author":"BS Schwartz","year":"2016","unstructured":"Schwartz, B. S. et al. Antibiotic use and childhood body mass index trajectory. Int J. Obes. (Lond.) 40, 615\u2013621 (2016).","journal-title":"Int J. Obes. (Lond.)"},{"key":"4284_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1530\/EJE-14-1163","volume":"172","author":"B Boursi","year":"2015","unstructured":"Boursi, B., Mamtani, R., Haynes, K. & Yang, Y.-X. The effect of past antibiotic exposure on diabetes risk. Eur. J. Endocrinol. 172, 639\u2013648 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"4284_CR4","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1210\/jc.2015-2696","volume":"100","author":"KH Mikkelsen","year":"2015","unstructured":"Mikkelsen, K. H., Knop, F. K., Frost, M., Hallas, J. & Potteg\u00e5rd, A. Use of antibiotics and risk of type 2 diabetes: a population-based case-control study. J. Clin. Endocrinol. Metab. 100, 3633\u20133640 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4284_CR5","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1093\/eurheartj\/ehz231","volume":"40","author":"Y Heianza","year":"2019","unstructured":"Heianza, Y. et al. Duration and life-stage of antibiotic use and risk of cardiovascular events in women. Eur. Heart J. 40, 3838\u20133845 (2019).","journal-title":"Eur. Heart J."},{"key":"4284_CR6","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cgh.2020.05.036","volume":"19","author":"M Song","year":"2021","unstructured":"Song, M., Nguyen, L. H., Emilsson, L., Chan, A. T. & Ludvigsson, J. F. Antibiotic use associated with risk of colorectal polyps in a nationwide study. Clin. Gastroenterol. Hepatol. 19, 1426\u20131435 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"4284_CR7","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41416-020-01082-2","volume":"123","author":"J Simin","year":"2020","unstructured":"Simin, J. et al. Antibiotic use and risk of colorectal cancer: a systematic review and dose-response meta-analysis. Br. J. Cancer 123, 1825\u20131832 (2020).","journal-title":"Br. J. Cancer"},{"key":"4284_CR8","doi-asserted-by":"publisher","first-page":"e1260","DOI":"10.1002\/mbo3.1260","volume":"11","author":"DV Patangia","year":"2022","unstructured":"Patangia, D. V., Anthony Ryan, C., Dempsey, E., Paul Ross, R. & Stanton, C. Impact of antibiotics on the human microbiome and consequences for host health. Microbiologyopen 11, e1260 (2022).","journal-title":"Microbiologyopen"},{"key":"4284_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","volume":"444","author":"PJ Turnbaugh","year":"2006","unstructured":"Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027\u20131031 (2006).","journal-title":"Nature"},{"key":"4284_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.123.063914","volume":"148","author":"S Sayols-Baixeras","year":"2023","unstructured":"Sayols-Baixeras, S. et al. Streptococcus species abundance in the gut is linked to subclinical coronary atherosclerosis in 8973 participants from the SCAPIS cohort. Circulation 148, 459\u2013472 (2023).","journal-title":"Circulation"},{"key":"4284_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.11.051","volume":"51","author":"M Gurung","year":"2020","unstructured":"Gurung, M. et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51, 102590 (2020).","journal-title":"EBioMedicine"},{"key":"4284_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41577-022-00727-y","volume":"23","author":"E Miyauchi","year":"2023","unstructured":"Miyauchi, E., Shimokawa, C., Steimle, A., Desai, M. S. & Ohno, H. The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat. Rev. Immunol. 23, 9\u201323 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"4284_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41586-024-07182-w","volume":"628","author":"M Zepeda-Rivera","year":"2024","unstructured":"Zepeda-Rivera, M. et al. A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature 628, 424\u2013432 (2024).","journal-title":"Nature"},{"key":"4284_CR14","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41591-025-03693-9","volume":"31","author":"G Piccinno","year":"2025","unstructured":"Piccinno, G. et al. Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer. Nat. Med 31, 2416\u20132429 (2025).","journal-title":"Nat. Med"},{"key":"4284_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110649","volume":"39","author":"WE Anthony","year":"2022","unstructured":"Anthony, W. E. et al. Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults. Cell Rep. 39, 110649 (2022).","journal-title":"Cell Rep."},{"key":"4284_CR16","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/infdis\/jix604","volume":"217","author":"J de Gunzburg","year":"2018","unstructured":"de Gunzburg, J. et al. Protection of the human gut microbiome from antibiotics. J. Infect. Dis. 217, 628\u2013636 (2018).","journal-title":"J. Infect. Dis."},{"key":"4284_CR17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/s41564-018-0257-9","volume":"3","author":"A Palleja","year":"2018","unstructured":"Palleja, A. et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat. Microbiol 3, 1255\u20131265 (2018).","journal-title":"Nat. Microbiol"},{"key":"4284_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/19490976.2016.1216747","volume":"7","author":"F Raymond","year":"2016","unstructured":"Raymond, F., D\u00e9raspe, M., Boissinot, M., Bergeron, M. G. & Corbeil, J. Partial recovery of microbiomes after antibiotic treatment. Gut Microbes 7, 428\u2013434 (2016).","journal-title":"Gut Microbes"},{"key":"4284_CR19","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMra1403772","volume":"372","author":"DA Leffler","year":"2015","unstructured":"Leffler, D. A. & Lamont, J. T. Clostridium difficile Infection. N. Eng. J. Med. 372, 1539\u20131548 (2015).","journal-title":"N. Eng. J. Med."},{"key":"4284_CR20","doi-asserted-by":"publisher","first-page":"e035677","DOI":"10.1136\/bmjopen-2019-035677","volume":"10","author":"KT Elvers","year":"2020","unstructured":"Elvers, K. T. et al. Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review. BMJ Open 10, e035677 (2020).","journal-title":"BMJ Open"},{"key":"4284_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark, B. et al. The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol. Drug Saf. 16, 726\u2013735 (2007).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"4284_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/joim.12384","volume":"278","author":"G Bergstr\u00f6m","year":"2015","unstructured":"Bergstr\u00f6m, G. et al. The Swedish CArdioPulmonary BioImage Study: objectives and design. J. Intern. Med. 278, 645\u2013659 (2015).","journal-title":"J. Intern. Med."},{"key":"4284_CR23","first-page":"16","volume":"1","author":"H Harris","year":"2013","unstructured":"Harris, H. et al. The Swedish mammography cohort and the cohort of Swedish men: study design and characteristics of two population-based longitudinal cohorts. OA Epidemiol. 1, 16 (2013).","journal-title":"OA Epidemiol."},{"key":"4284_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10654-020-00695-4","volume":"36","author":"L Brunkwall","year":"2021","unstructured":"Brunkwall, L. et al. The Malm\u00f6 Offspring Study (MOS): design, methods and first results. Eur. J. Epidemiol. 36, 103\u2013116 (2021).","journal-title":"Eur. J. Epidemiol."},{"key":"4284_CR25","first-page":"1887","volume":"45","author":"J Textor","year":"2016","unstructured":"Textor, J., van der Zander, B., Gilthorpe, M. S., Li\u015bkiewicz, M. & Ellison, G. T. Robust causal inference using directed acyclic graphs: the R package \u2018dagitty\u2019. Int. J. Epidemiol. 45, 1887\u20131894 (2016).","journal-title":"Int. J. Epidemiol."},{"key":"4284_CR26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41586-021-04177-9","volume":"600","author":"SK Forslund","year":"2021","unstructured":"Forslund, S. K. et al. Combinatorial, additive and dose-dependent drug\u2013microbiome associations. Nature 600, 500\u2013505 (2021).","journal-title":"Nature"},{"key":"4284_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CLEP.S282475","volume":"13","author":"JF Ludvigsson","year":"2021","unstructured":"Ludvigsson, J. F. et al. Adaptation of the Charlson Comorbidity Index for register-based research in Sweden. Clin. Epidemiol. 13, 21\u201341 (2021).","journal-title":"Clin. Epidemiol."},{"key":"4284_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson, M. E., Carrozzino, D., Guidi, J. & Patierno, C. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother. Psychosom. 91, 8\u201335 (2022).","journal-title":"Psychother. Psychosom."},{"key":"4284_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71571-4","volume":"14","author":"A Larsson","year":"2024","unstructured":"Larsson, A. et al. New connections of medication use and polypharmacy with the gut microbiota composition and functional potential in a large population. Sci. Rep. 14, 23723 (2024).","journal-title":"Sci. Rep."},{"key":"4284_CR30","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1053\/j.gastro.2022.06.070","volume":"163","author":"N Nagata","year":"2022","unstructured":"Nagata, N. et al. Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology 163, 1038\u20131052 (2022).","journal-title":"Gastroenterology"},{"key":"4284_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","volume":"65","author":"F Imhann","year":"2016","unstructured":"Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740\u2013748 (2016).","journal-title":"Gut"},{"key":"4284_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623\u2013628 (2018).","journal-title":"Nature"},{"key":"4284_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28464-9","volume":"13","author":"O Aasmets","year":"2022","unstructured":"Aasmets, O., Krigul, K. L., L\u00fcll, K., Metspalu, A. & Org, E. Gut metagenome associations with extensive digital health data in a volunteer-based Estonian microbiome cohort. Nat. Commun. 13, 869 (2022).","journal-title":"Nat. Commun."},{"key":"4284_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14177-z","volume":"11","author":"A Vich Vila","year":"2020","unstructured":"Vich Vila, A. et al. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat. Commun. 11, 362 (2020).","journal-title":"Nat. Commun."},{"key":"4284_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jpsychires.2025.05.046","volume":"189","author":"F McDonagh","year":"2025","unstructured":"McDonagh, F., Murray, E. K., Hallahan, B. & Miliotis, G. Systematic examination of off-target effects of antipsychotic medications associated with microbiome disruption and heightened bacterial infection risks. J. Psychiatr. Res 189, 171\u2013183 (2025).","journal-title":"J. Psychiatr. Res"},{"key":"4284_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41574-024-00966-0","volume":"20","author":"LMM Vliex","year":"2024","unstructured":"Vliex, L. M. M., Penders, J., Nauta, A., Zoetendal, E. G. & Blaak, E. E. The individual response to antibiotics and diet - insights into gut microbial resilience and host metabolism. Nat. Rev. Endocrinol. 20, 387\u2013398 (2024).","journal-title":"Nat. Rev. Endocrinol."},{"key":"4284_CR37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000443360","volume":"34","author":"K Lange","year":"2016","unstructured":"Lange, K., Buerger, M., Stallmach, A. & Bruns, T. Effects of antibiotics on gut microbiota. Dig. Dis. 34, 260\u2013268 (2016).","journal-title":"Dig. Dis."},{"key":"4284_CR38","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrmicro.2017.58","volume":"15","author":"F Sommer","year":"2017","unstructured":"Sommer, F., Anderson, J. M., Bharti, R., Raes, J. & Rosenstiel, P. The resilience of the intestinal microbiota influences health and disease. Nat. Rev. Microbiol 15, 630\u2013638 (2017).","journal-title":"Nat. Rev. Microbiol"},{"key":"4284_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29229-5","volume":"8","author":"CW MacPherson","year":"2018","unstructured":"MacPherson, C. W. et al. Gut bacterial microbiota and its resistome rapidly recover to basal state levels after short-term amoxicillin-clavulanic acid treatment in healthy adults. Sci. Rep. 8, 11192 (2018).","journal-title":"Sci. Rep."},{"key":"4284_CR40","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1093\/jac\/dkab173","volume":"76","author":"R Bruyndonckx","year":"2021","unstructured":"Bruyndonckx, R. et al. Consumption of penicillins in the community, European Union\/European Economic Area, 1997\u20132017. J. Antimicrob. Chemother. 76, ii14\u2013ii21 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"4284_CR41","doi-asserted-by":"publisher","unstructured":"Xue, K. S. et al. Prolonged delays in human microbiota transmission after a controlled antibiotic perturbation. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.09.26.559480 (2023).","DOI":"10.1101\/2023.09.26.559480"},{"key":"4284_CR42","first-page":"22","volume":"9","author":"M Smieja","year":"1998","unstructured":"Smieja, M. Current indications for the use of clindamycin: a critical review. Can. J. Infect. Dis. 9, 22\u201328 (1998).","journal-title":"Can. J. Infect. Dis."},{"key":"4284_CR43","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1086\/319370","volume":"32","author":"DC Hooper","year":"2001","unstructured":"Hooper, D. C. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis. 32, S9\u2013S15 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"4284_CR44","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.cell.2024.03.014","volume":"187","author":"C Li","year":"2024","unstructured":"Li, C. et al. Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria. Cell 187, 1834\u20131852 (2024).","journal-title":"Cell"},{"key":"4284_CR45","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/s41591-024-03067-7","volume":"30","author":"Z Mei","year":"2024","unstructured":"Mei, Z. et al. Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes. Nat. Med. 30, 2265\u20132276 (2024).","journal-title":"Nat. Med."},{"key":"4284_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S2213-8587(22)00113-9","volume":"10","author":"L Grahnemo","year":"2022","unstructured":"Grahnemo, L. et al. Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome. Lancet Diab. Endocrinol. 10, 481\u2013483 (2022).","journal-title":"Lancet Diab. Endocrinol."},{"key":"4284_CR47","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1136\/gutjnl-2022-327845","volume":"72","author":"AS Faye","year":"2023","unstructured":"Faye, A. S. et al. Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study. Gut 72, 663\u2013670 (2023).","journal-title":"Gut"},{"key":"4284_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54797-8","volume":"15","author":"S Akiyama","year":"2024","unstructured":"Akiyama, S. et al. Multi-biome analysis identifies distinct gut microbial signatures and their crosstalk in ulcerative colitis and Crohn\u2019s disease. Nat. Commun. 15, 10291 (2024).","journal-title":"Nat. Commun."},{"key":"4284_CR49","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1371\/journal.pbio.0060280","volume":"6","author":"L Dethlefsen","year":"2008","unstructured":"Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).","journal-title":"PLoS Biol."},{"key":"4284_CR50","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/ismej.2007.3","volume":"1","author":"C Jernberg","year":"2007","unstructured":"Jernberg, C., L\u00f6fmark, S., Edlund, C. & Jansson, J. K. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 1, 56\u201366 (2007).","journal-title":"ISME J."},{"key":"4284_CR51","doi-asserted-by":"publisher","first-page":"e9836","DOI":"10.1371\/journal.pone.0009836","volume":"5","author":"HE Jakobsson","year":"2010","unstructured":"Jakobsson, H. E. et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS ONE 5, e9836 (2010).","journal-title":"PLoS ONE"},{"key":"4284_CR52","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1128\/JCM.43.11.5588-5592.2005","volume":"43","author":"MF De La Cocheti\u00e8re","year":"2005","unstructured":"De La Cocheti\u00e8re, M. F. et al. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J. Clin. Microbiol. 43, 5588\u20135592 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"4284_CR53","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01693-15","volume":"6","author":"E Zaura","year":"2015","unstructured":"Zaura, E. et al. Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces. mBio 6, e01693-15 (2015).","journal-title":"mBio"},{"key":"4284_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni, A. A. & Jackson, S. H. D. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br. J. Clin. Pharm. 57, 6\u201314 (2004).","journal-title":"Br. J. Clin. Pharm."},{"key":"4284_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/10408347.2018.1468728","volume":"49","author":"Menezes","year":"2019","unstructured":"Menezes et al. Flucloxacillin: a review of characteristics, properties and analytical methods. Crit. Rev. Anal. Chem. 49, 67\u201377 (2019).","journal-title":"Crit. Rev. Anal. Chem."},{"key":"4284_CR56","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jac\/dkl224","volume":"58","author":"KN Agwuh","year":"2006","unstructured":"Agwuh, K. N. & MacGowan, A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J. Antimicrob. Chemother. 58, 256\u2013265 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"4284_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra, I. & Roberts, M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol. Biol. Rev. 65, 232\u2013260 (2001).","journal-title":"Microbiol Mol. Biol. Rev."},{"key":"4284_CR58","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1128\/CMR.00086-12","volume":"26","author":"I Brook","year":"2013","unstructured":"Brook, I., Wexler, H. M. & Goldstein, E. J. C. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin. Microbiol. Rev. 26, 526\u2013546 (2013).","journal-title":"Clin. Microbiol. Rev."},{"key":"4284_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61137-x","volume":"16","author":"K P\u00e4rn\u00e4nen","year":"2025","unstructured":"P\u00e4rn\u00e4nen, K. et al. Variation and prognostic potential of the gut antibiotic resistome in the FINRISK 2002 cohort. Nat. Commun. 16, 5963 (2025).","journal-title":"Nat. Commun."},{"key":"4284_CR60","doi-asserted-by":"publisher","DOI":"10.1128\/msystems.00541-25","volume":"0","author":"O Aasmets","year":"2025","unstructured":"Aasmets, O. et al. A hidden confounder for microbiome studies: medications used years before sample collection. mSystems 0, e0054125 (2025).","journal-title":"mSystems"},{"key":"4284_CR61","unstructured":"Ekman, G. S. & Kanebj\u00f6rk, J. K. Stramas statistik \u00f6ver antibiotikaanv\u00e4ndning och resistens. Region Uppsala https:\/\/regionuppsala.se\/samverkanswebben\/for-vardgivare\/kunskapsstod\/strama-region-uppsala\/stramas-statistik-over-antibiotikaanvandning-och-resistens\/ (2023)."},{"key":"4284_CR62","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3389\/fmicb.2017.02224","volume":"8","author":"GB Gloor","year":"2017","unstructured":"Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V. & Egozcue, J. J. Microbiome datasets are compositional: and this is not optional. Front. Microbiol. 8, 2224 (2017).","journal-title":"Front. Microbiol."},{"key":"4284_CR63","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2460\/javma.2005.227.34","volume":"227","author":"CB Andreasen","year":"2005","unstructured":"Andreasen, C. B., Spickler, A. R. & Jones, B. E. Swedish animal welfare regulations and their impact on food animal production. J. Am. Vet. Med. Assoc. 227, 34\u201340 (2005).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"4284_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/00008469-200112000-00003","volume":"10","author":"J Manjer","year":"2001","unstructured":"Manjer, J. et al. The Malm\u00f6 Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur. J. Cancer Prev. 10, 489\u2013499 (2001).","journal-title":"Eur. J. Cancer Prev."},{"key":"4284_CR65","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/gutjnl-2016-312135","volume":"67","author":"F Imhann","year":"2018","unstructured":"Imhann, F. et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 67, 108\u2013119 (2018).","journal-title":"Gut"},{"key":"4284_CR66","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1164\/rccm.202206-1066TR","volume":"207","author":"L Wang","year":"2023","unstructured":"Wang, L. et al. The bidirectional gut-lung axis in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med 207, 1145\u20131160 (2023).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"4284_CR67","doi-asserted-by":"publisher","first-page":"1425489","DOI":"10.3389\/fmicb.2024.1425489","volume":"15","author":"S Pita","year":"2024","unstructured":"Pita, S. et al. CHAMP delivers accurate taxonomic profiles of the prokaryotes, eukaryotes, and bacteriophages in the human microbiome. Front. Microbiol. 15, 1425489 (2024).","journal-title":"Front. Microbiol."},{"key":"4284_CR68","doi-asserted-by":"publisher","first-page":"D785","DOI":"10.1093\/nar\/gkab776","volume":"50","author":"DH Parks","year":"2022","unstructured":"Parks, D. H. et al. GTDB: an ongoing census of bacterial and archaeal diversity through a phylogenetically consistent, rank normalized and complete genome-based taxonomy. Nucleic Acids Res. 50, D785\u2013D794 (2022).","journal-title":"Nucleic Acids Res."},{"key":"4284_CR69","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04284-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04284-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:02:14Z","timestamp":1780578134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04284-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4284"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04284-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of the article initially published, Supplementary Table 12 contained an error in which cohort-specific results for the SIMPLER cohort were inadvertently duplicated and the corresponding results for the MOS cohort were omitted. The error occurred during compilation of the supplementary table and does not affect the meta-analysis results or the conclusions of the study. Supplementary Table 12 has now been corrected online. The Code availability statement has also been updated to note the available code was used to generate figures and tables in the article. The changes are made in the HTML and PDF versions of the article.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. reports direct or indirect stock ownership in companies (Anagram Kommunikation AB, Sence Research AB, Symptoms Europe AB, MinForskning AB) that provide services not related to the present work to companies and authorities in the health sector, including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, G\u00f6teborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Link\u00f6ping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma and WeMind. J.\u00c4. has served on the advisory boards for Astella, AstraZeneca and Boehringer Ingelheim and has received lecturing fees from AstraZeneca and Novartis, all unrelated to the present work. J.F.L. has also received financial support from M.S.D. to develop a paper reviewing national healthcare registers in China, has ongoing discussions with M.S.D. about unrelated IBD research and receives funding for celiac disease research from Takeda. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}